128 million euro round for Tubulis

Tubulis on course for expansion: New financing round supports Munich-based company in clinical evaluation and US market entry. Bayern Kapital continues to invest.

Munich, March 14, 2024 - Munich-based biotech company Tubulis has closed an expanded and oversubscribed Series B2 financing round of 128 million euros. The Series B2 financing round was oversubscribed and led by various investors, including EQT Life Sciences and Nextech Invest Ltd. Bayern Kapital also participated as a long-standing investor.

The current financing round by various international investors specializing in the biotech segment once again underlines Tubulis' unique positioning in the ADC sector.

Dr. Dominik Schumacher, CEO and co-founder of Tubulis

Antibodies for cancer therapy

Tubulis focuses on the development of antibody drug conjugates (ADCs) for cancer therapy. These are designed to attack cancer cells in a more targeted manner while sparing the surrounding healthy tissue. The funds from the financing round will be used for the clinical evaluation of the lead candidates TUB-030 and TUB-040 as well as the further development of the technology platform and expansion into the US market.

The company aims to further advance its technology and establish itself as a major player in cancer therapy.

Further comments on the round

Important personalities commented on Tubulis' involvement in the financing round and its impact on Bavaria's biotech sector. Bavaria's Minister of Economic Affairs, Hubert Aiwanger, praised Tubulis' innovative strength and emphasized the importance of such success stories for the state. He emphasized that investments such as these strengthen Bavaria's position in the field of science and technology and contribute to the creation of jobs in the long term. Monika Steger, Managing Director of Bayern Kapital, emphasized the importance of Tubulis' platform technology for cancer research and treatment. She emphasized that the company has been supported by the ScaleUp Fund Bavaria since the first financing round in 2020 and that she is pleased to continue this cooperation in the current round.